Transcranial Magnetic Stimulation to Enhance Cortical Hippocampal Functional Connectivity as a Novel Means for Relieving Chronic OA Pain
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Chronic Pain
- Sponsor
- Northwestern University
- Locations
- 1
- Primary Endpoint
- Pain ratings (Numeric Rating Scale)
- Status
- Withdrawn
- Last Updated
- 3 years ago
Overview
Brief Summary
In this study the investigators aim to examine the effects of Transcranial Magnetic Stimulation (TMS) on hippocampal network connectivity and pain levels in individuals with pain due to knee osteoarthritis.
Detailed Description
Osteoarthritis (OA) pain is one of the most prevalent causes of chronic pain worldwide. Symptoms can last from months to a lifetime, severely impacting patients' quality of life. New strategies - including non-invasive brain stimulation techniques - have shown promise for sustained pain relief, yet evidence on their reliability and efficacy is limited. Apkarian et. al have previously shown that the dorsal hippocampus plays a central role in pain analgesia; thus, the study aim is to test whether non-invasively enhancing dorsal hippocampus activity is a useful new strategy for pain relief in knee OA patients. This study will recruit 35 patients with chronic OA pain for \> 6 months. Each participant will receive 3 rounds of different treatment modalities in a cross-over manner. Each treatment modality will consist of 5 daily consecutive rTMS sessions followed by a 2-weeks wash-out period. Questionnaires will be completed prior to and following each intervention, and after each treatment round. Participants will be trained to use a pain electronic application (smartphone-based tool to rate pain intensity and mood on NRS scales, as well as indicate rescue medication use, developed in our lab). They will be asked to use this application for 7-10 days prior to the first round of intervention and during the study duration.
Investigators
Apkar Apkarian
Director Center for Translational Pain Research, Director Center of Excellence for Chronic Pain and Drug Abuse Research, Professor of Neuroscience, Anesthesia, PM&R
Northwestern University
Eligibility Criteria
Inclusion Criteria
- •≥ 6 months of knee pain on a daily basis;
- •male or female with no racial or ethnic restrictions;
- •18 to 75 years old;
- •average knee pain intensity \> 4/10 at study entry;
- •must be able to read, understand, and sign consent form;
- •generally healthy.
- •able to use the PainApp
Exclusion Criteria
- •rheumatoid arthritis, ankylosing spondylitis, acute vertebral fractures,
- •Chronic neurologic conditions, e.g., Parkinson's
- •other severe medical diseases;
- •pregnancy;
- •positive urinary screen for any recreational drugs,
- •opioids use;
- •use of anticoagulants (low dose ASA allowed);
- •history of gastric ulcer; renal insufficiency or congestive heart failure,
- •contraindication to MRI,
- •contraindication to TMS; including history of seizure/epilepsy\*
Outcomes
Primary Outcomes
Pain ratings (Numeric Rating Scale)
Time Frame: Pain ratings immediately after each rTMS modality and effects after the end of stimulation round (1 week).
The primary efficacy outcomes are the effects of the rTMS modalities on pain app ratings.
Secondary Outcomes
- Pain trajectories(1 to 12 weeks (end of the study))
- Adverse events(1 to 12 weeks (end of the study))
- Brain biomarkers and psychological indicators of rTMS effects and pain relief(1 to 12 weeks (end of the study))
- Global impression of change(1 to 12 weeks - after each rTMS round.)